晚期非小细胞肺癌化疗的冷思考  

The Rational Thinking of Chemotherapy in Advanced Non-Small Cell Lung Cancer

作　　者：周涛[1] 刘素勤[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁大连116011

出　　处：《医学与哲学（B）》2006年第3期24-27,共4页Medicine & Philosophy(B)

摘　　要：晚期非小细胞肺癌提倡以化疗为主综合治疗,可以延长生存期,提高生存率。但目前化疗取得的疗效虽然较既往有提高,但提高生存期有限,且在药效经济学方面存在争议,缓解症状的作用也有限,联合靶向治疗的疗效也在观望中。临床肿瘤学工作者应正确认识,以循证医学为指导,开展规范化化疗,同时也注重个体化化疗,并期待晚期非小细胞肺癌化疗的新突破。The multidisciplinary treatment plays an important role in advanced non- small cell lung cancer and chenlotherapy is the main treatment. The response rate of chenaotherapy in advanced non - small cell lung cancer is not satisfied and the improvement of survival time and quality of life （QOL） is limited. Targeted therapy in advanced non - small cell lung cancer is just a beginning. Survival time and quality of life are the main role in the treatment of advanced non - small cell lung cancer. Clinical oncologists should deliver chemotherapy bared on EBM and standardization for patients with advanced non- small cell lung cancer, pay attention to individualization, and hope new approach in this area.

关 键 词：晚期非小细胞肺癌 化学治疗 疗效 循证医学 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]